Welcome to our dedicated page for PepGen SEC filings (Ticker: PEPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PepGen Inc. filings document the regulatory record of a clinical-stage biotechnology company developing Enhanced Delivery Oligonucleotide therapies for neuromuscular and neurological diseases. Its Form 8-K disclosures cover financial results, corporate presentations, clinical data updates for PGN-EDODM1, FDA-related regulatory matters involving FREEDOM2-DM1, and other business updates tied to its development pipeline.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board structure, executive compensation and stockholder voting mechanics. Other filings address officer appointments, inducement grants, stock-option plans, option repricing, common-stock compensation arrangements and related governance approvals. Together, the filings outline PepGen’s clinical-development disclosures, capital and equity incentive structure, risk-facing regulatory events and public-company governance practices.
PepGen Inc. reported a compensation-related transaction involving an option grant linked to RA Capital-managed entities. An option over 34,000 shares of common stock was awarded at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option will vest in full on the earlier of the first anniversary of the grant date or PepGen’s next annual stockholder meeting, subject to continued board service by Dr. Resnick. Under his arrangement with RA Capital, any net cash or stock from exercising the option will benefit RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, offsetting advisory fees, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
PepGen Inc. held its 2026 Annual Meeting of Stockholders on June 18, 2026, where shareholders voted on director elections and auditor ratification. A quorum was reached, with 54,650,845 shares present or represented by proxy out of 69,169,215 shares entitled to vote.
Stockholders elected three Class I directors—Howard Mayer, M.D., Joshua Resnick, M.D., M.B.A., and Lisa Wyman, M.S.—to serve until the 2029 annual meeting. Each nominee received tens of millions of votes in favor, with additional broker non-votes recorded.
Stockholders also ratified the appointment of KPMG LLP as PepGen’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 54,556,255 votes for, 77,083 against, and 17,507 abstentions.
PepGen Inc. reported that director Lisa Wyman received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. They vest in full on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued service as a director.
PepGen Inc. reported that director Joshua Resnick received a grant of stock options covering 34,000 shares of Common Stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, with vesting stopping if he ceases to serve as a director unless the Board decides otherwise. Under his arrangement with RA Capital Management, L.P., Resnick holds this option for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II, and a separately managed account, must turn over any net cash or stock on exercise to RA Capital, and disclaims beneficial ownership of the option and underlying shares.
PepGen Inc. director Howard Mayer received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036. This grant is compensation-related and does not represent an open-market purchase or sale of shares.
According to the vesting terms, the option vests in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting, with vesting stopping if he ceases to serve as a director unless the board decides otherwise. Following this grant, Mayer holds 34,000 options directly.
PepGen Inc. director Mitchell H. Finer received a grant of stock options covering 34,000 shares of common stock. The options carry an exercise price of $1.79 per share and expire on June 17, 2036.
The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, and vesting stops if he ceases to serve as a director unless the board decides otherwise. Following this grant, he holds 34,000 stock options directly, as reported in this filing.
PepGen Inc. director Habib J. Dable received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
The award vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued board service unless the board decides otherwise. Following this grant, Dable holds 34,000 options directly, and the filing shows no open-market buying or selling.
PepGen Inc. director Heidi Henson received a grant of stock options covering 34,000 shares of common stock. The options have an exercise price of $1.79 per share and expire on June 17, 2036.
These options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting, subject to continued service on the board unless the board determines otherwise.
PepGen Inc. director Laurie Keating reported a new compensation award on a Form 4. She received a stock option to buy 34,000 shares of PepGen common stock at an exercise price of $1.79 per share, expiring on June 17, 2036.
The option vests in full on the earlier of the first anniversary of the grant date or the date of the next Annual Meeting, as long as she continues serving as a director, unless the board decides otherwise. After this grant, Keating holds options covering 34,000 underlying shares from this award.
PepGen Inc. Chief Technical Officer Kasraian Kasra reported an automatic sale of 1,233 shares of Common Stock on May 21, 2026 at a weighted average price of $1.4107 per share, with individual trades ranging from $1.41 to $1.4541.
According to the disclosure, the shares were sold by the company under a mandatory sell-to-cover provision tied to vested restricted stock units, solely to satisfy minimum statutory tax withholding obligations. The filing states this sale was made under an RSU agreement treated as a binding contract consistent with the Rule 10b5-1 affirmative defense and does not represent a discretionary trade by the insider. Following the transaction, Kasraian Kasra directly holds 50,074 shares of PepGen common stock.